Navigation Links
Intellect Neurosciences Submits Statement Setting Grounds for Appeal in European Patent Proceedings
Date:2/14/2012

NEW YORK, Feb. 14, 2012 /PRNewswire/ -- Intellect Neurosciences, Inc. (OTCBB: ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases announced today that it submitted a statement setting out its grounds for appealing the European Patent Office's (EPO) preliminary decision to revoke the company's ANTISENILIN® patents regarding passive immunotherapy methods for the treatment of Alzheimer's disease. That decision followed a challenge by major pharmaceutical companies co-developing bapineuzumab, currently in Phase 3 clinical trials.

(Logo: http://photos.prnewswire.com/prnh/20111214/NY22484LOGO )

The submitted Statement explains in detail why the Opposition Proceedings initiated by Elan and Wyeth on April 30, 2009 and maintained by Pfizer and Johnson & Johnson are not supported by the facts.  Intellect Neurosciences remains confident that its grounds of appeal will lead to a reversal of the preliminary decision by the EPO that was based on a primarily formalistic objection.  It is worth noting that the Notice of Opposition to Intellect's patents did not include allegations regarding lack of inventiveness or novelty.

"We are determined to protect our dominating patent position despite the bullying tactics by major pharmaceutical companies aiming to intimidate and undermine a company with the small size and limited resources of Intellect Neurosciences. Those actions are disappointing because we had previously demonstrated our willingness to provide licenses under favorable terms to various developers of antibodies based on our ANTISENILIN® platform technology," commented Daniel G. Chain, Ph.D., Intellect's chairman & CEO.  "We intend to vigorously pursue a reversal of the EPO's preliminary decision, and we intend to vig
'/>"/>

SOURCE Intellect Neurosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
3. Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimers Therapeutic Antibody
4. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
5. Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
6. New Study Confirms That the Supports Intensity Scale Assessment is Effective in Measuring the Support Needs of People With Intellectual Disability and Making Funding Decisions
7. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
8. NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds
9. VisEn Acquires Key Fluorescence Agent Intellectual Property Portfolio and Technology Platforms From Bayer Schering Pharma
10. First iPierian Patent for Induced Pluripotent Stem Cell Technology Granted by United Kingdom Intellectual Property Office
11. Limited Healthcare Infrastructure and Weak Intellectual Property Protection are Among the Challenges Pharma Faces with Emerging Market Expansion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), a ... blood purification technology to help fight deadly inflammation ... countries worldwide, today announced the appointment of Dr. ... as its Senior Vice President of Clinical Development, ... Di Russo is an accomplished pediatric ...
(Date:12/22/2014)... , Dec. 22, 2014 Apnea Sciences ( ... offices in Aliso Viejo , California.  ... to the tremendous growth and worldwide expansion, a new ... patented SnoreRx, the anti snore cure have exceeded our ... "We are now in 23 countries and will ...
(Date:12/22/2014)... 22, 2014   TRU-D SmartUVC LLC, producers ... robot, announced today that the General Services Administration has ... 2019.   This newly formed agreement will ... of government purchasers, including Department of Veteran Affairs and ... Security contacts purchasing solutions for the Ebola effort in ...
Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2
... Like many other diagnostic regimes that were previously ... entering the clinical mainstream. Smaller, simpler analyzer systems ... large physicians group labs, while some genetic test ... care locations such as clinics and physician offices., ...
... to plan or evaluate anticoagulant therapy, to ... elevated factor VIII levels, dysfibrinogenemia, factor XII ... to assess acquired conditions, such as pregnancy, ... Prothrombin levels are also monitored along with ...
Cached Medicine Technology:Genetic Analysis Systems Enter the Clinical Mainstream 2Genetic Analysis Systems Enter the Clinical Mainstream 3Prothrombin Time Comes in Small (CLIA-Waived) Packages 2Prothrombin Time Comes in Small (CLIA-Waived) Packages 3
(Date:12/25/2014)... 2014 The report “TS-1 (Colorectal Cancer) ... the current treatment landscape, unmet needs, current pipeline and ... an anti-cancer drug which is typically used for treating ... used for treating gastric cancer and pancreatic cancer. TS-1 ... drug was first approved in 1999 in Japan for ...
(Date:12/25/2014)... 26, 2014 Recently, iFitDress.com, the popular online ... has announced its new selection of black one-shoulder cocktail ... sale now; they are available at discounted prices, up to ... promotion will last for three weeks only. You know, we ... who are interested in our new items can visit our ...
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas ... BellasDress has chosen their best-selling lace wedding dresses, vintage ... holiday season. , Now, BellasDress.com features popular women’s ... at discount prices. The business hopes everyone can have ... , “All our elegant products are made with ...
(Date:12/25/2014)... FL (PRWEB) December 25, 2014 When head ... find themselves in a frenzy to get rid of it ... But families in Coral Gables now have the solution right ... second salon clinic location, Lice Troopers provides full spectrum head ... the Coral Gable area, including Sunset, Key Biscayne, Brickell, Coconut ...
(Date:12/25/2014)... THURSDAY, Dec. 25, 2014 (HealthDay News) -- The risk ... the holidays, so you need to be extra cautious, ... Day, we see a significant increase in patients coming ... at the Suffolk County Volunteer Firefighters Burn Center of ... celebrations should be full of joy, but if not ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Don't Let Burns Mar Your Holidays 2
... being male did have a correlation , , FRIDAY, March ... extent of head flattening in infants, U.S. researchers say. ... asymmetrical head shape, known as deformational plagiocephaly (DP), in ... Since the early 1990s, parents have been encouraged to ...
... stents were safe and superior to bare metal stents ... patients enrolled in a nationwide registry of cardiovascular disease, ... , The findings were presented today at the i2Summit ... Session. They also appear online in the Journal ...
... Sciences, Inc. (OTC Bulletin Board: EROX) ("HPS" or "the Company") ... ended December 31, 2008. For the three months ended December ... from revenues of $389,000 in the prior year period, and ... compared with net income of $38,000 ($0.01 per share) for ...
... March 27 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) ... company announced the clinical trial protocol for their MMR ... approved by the end of the second quarter 2009. ... live attenuated viruses administered via injection for immunization against ...
... and Social Responsibility Targets to be met by ... Gamble Company (NYSE: PG ) today ... goals. The updates reflect the company,s continued ... of P&G,s products and operations and bettering lives ...
... of the Simulated Impaired Driving Experience(R), (SIDNE(R)), will be ... the Lifesavers conference at the Gaylord Opryland Resort and ... 31. The Lifesavers Conference is a national traffic safety ... our nation,s roadways. "We are excited to demonstrate our ...
Cached Medicine News:Health News:Baby's Sleep Position May Not Affect Severity of Head Flattening 2Health News:Drug-eluting stents found safe, superior to bare metal stents 2Health News:Human Pheromone Sciences Announces Fourth Quarter and Full Year Results 2Health News:Human Pheromone Sciences Announces Fourth Quarter and Full Year Results 3Health News:Human Pheromone Sciences Announces Fourth Quarter and Full Year Results 4Health News:Human Pheromone Sciences Announces Fourth Quarter and Full Year Results 5Health News:Hard to Treat Diseases (HTDS) clinical trial protocol for MMR Vaccine expected Q2 2009 2Health News:Procter & Gamble Deepens Corporate Commitment to Sustainability 2Health News:Procter & Gamble Deepens Corporate Commitment to Sustainability 3Health News:Innocorp, ltd. to Attend Lifesavers Conference 2
The Thermal pads were designed to simulate water immersion, the most effective method of transferring energy non-invasively....
This blanket is ideal for warming the large child or small adult during upper body surgery....
The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets....
The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets....
Medicine Products: